Showing results (1321-1330 of 1,351) with videos related to

Sort By:
Pageof 136
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
A transposase-derived gene required for human brain developmentLuz Jubierre Zapater, Sara A Lewis, Rodrigo Lopez Gutierrez, et al.
Science Advances|January 14, 2026
A transposase-derived gene required for human brain developmentLuz Jubierre Zapater, Sara A Lewis, Rodrigo Lopez Gutierrez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Annals of Surgical Oncology|October 31, 2013
Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French studyGéraldine Pignot, Laurent Salomon, Yann Neuzillet, et al.
Molecular Genetics and Metabolism|October 12, 2013
Dietary management of urea cycle disorders: European practiceS Adam, M F Almeida, M Assoun, et al.
Communications Biology|January 23, 2021
Chromosomal scale assembly of parasitic wasp genome reveals symbiotic virus colonizationJérémy Gauthier, Hélène Boulain, Joke J F A van Vugt, et al.
European Urology|March 8, 2011
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general populationYann Neuzillet, Xavier Tillou, Romain Mathieu, et al.
Nature Medicine|June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Pageof 136